# 

**PB 8 of 2016**

National Health (Originator Brand) Amendment Determination 2016 (No. 1)

*National Health Act 1953*

I, DIANNA PROSSER, Assistant Secretary (Acting) , Pharmaceutical Policy Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the *National Health Act 1953*.

Dated   28 January 2016

**DIANNA PROSSER**

Assistant Secretary (Acting)

Pharmaceutical Policy Branch

Pharmaceutical Benefits Division

Department of Health

1 Name of Determination

(1) This Determination is the *National Health (Originator Brand) Amendment Determination 2016 (No. 1).*

(2) This Determination may also be cited as PB 8 of 2016.

2 Commencement

This Determination commences on 1 February 2016.

3 Amendments to PB 100 of 2015

Schedule 1 amends the *National Health (Originator Brand) Determination 2015* (PB 100 of 2015).

Schedule 1 Amendments

(section 3)

[1] Schedule 1 (after table item 16)

*Insert:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 16A | Apomorphine | Apomine |  |  |

[2] Schedule 1, table item 83 [entry for fentanyl]

*Insert as first item, in the columns in the order indicated*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | Abstral | Sublingual |  |

[3] Schedule 1 (after table item 246)

*Insert:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 246A | Voriconazole | Vfend |  |  |